Evidence-Based Innovation
Advancing the Science of Healing
Our field is dedicated to the highest standards of clinical data and curated research. May we bridge the gap between ancient wisdom and modern rigorous evidence to redefine mental health care through psychedelic-assisted psychotherapy.
.webp)
Research & Articles
71%
Clinical Success
Participants showing significant reduction in PTSD symptoms after three sessions of MDMA-assisted therapy in phase 3 trials.
12mo
Sustained Healing
Follow-up data indicates that clinical improvements remain stable for at least one year following the treatment protocol.
85%
Therapeutic Alliance
High scores in patient-reported therapeutic alliance, correlating with the deep relational work facilitated by psychedelics.
“Just because something isn’t a medical model doesn’t mean you can’t have mental health benefits” -Korthuis
Study finds sustained benefit for people using Oregon psilocybin services
OHSU-led research is the largest study of psychedelics outside clinical trials
The study enlisted 346 people who joined licensed facilitators for a single session using psilocybin between November 2024 and June 2026. Participants reported their state of mind at baseline, one week, one month and three months after single psilocybin sessions at 24 licensed service centers in Oregon.
Participants reported their experience through a web-based portal, with 90% continuing to do so through three months. Key findings:
-
At one month, 91.5% felt they benefited and 64.9% ranked the experience among the 10 most meaningful of their life.
-
At three months, participants reported decreased moderate-to-severe symptoms of depression, anxiety and PTSD. They also reported improved mental well-being and life satisfaction.
-
Few reported their experience as harmful, although four who used psilocybin for the first time experienced adverse behavioral reactions that required medical attention. No participants reported a serious event related to their physical health.